Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial

scientific article published on 28 August 2020

Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/S0140-6736(20)31790-6
P698PubMed publication ID32877651

P50authorPetr WidimskýQ12045089
Michał TenderaQ48860774
P2093author name stringRoberto Ferrari
Ian Ford
Nicolas Danchin
Kim Fox
Anne Correges
ATPCI investigators
Jean Pascal Challeton
P2860cites workPercutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of randomized clinical trialsQ28272636
The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolaseQ28373346
Prevalence of anginal symptoms and myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary artery disease: data from the International Observational CLARIFY RegistryQ30841815
Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35 mg in patients with stable angina pectoris: a multicenter, double-blind, placebo-controlled studyQ34290387
Optimal medical therapy with or without PCI for stable coronary diseaseQ34612445
Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trialQ35810820
Percutaneous coronary intervention with second-generation drug-eluting stent versus bare-metal stent: Systematic review and cost-benefit analysisQ36370257
Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLandQ43811969
Efficacy comparison of trimetazidine with therapeutic alternatives in stable angina pectoris: a network meta-analysisQ45829479
Expert consensus document: A 'diamond' approach to personalized treatment of anginaQ48022963
2018 ESC/EACTS Guidelines on myocardial revascularizationQ57071561
Stent-Related Adverse Events >1 Year After Percutaneous Coronary InterventionQ89711644
Initial Invasive or Conservative Strategy for Stable Coronary DiseaseQ90754553
Mechanisms and diagnostic evaluation of persistent or recurrent angina following percutaneous coronary revascularizationQ90877897
A randomized, double-blind, placebo-controlled trial to assess the efficAcy and safety of Trimetazidine in patients with angina pectoris having been treated by percutaneous coronary intervention (ATPCI study): Rationale, design, and baseline charactQ91644078
Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trialQ91856170
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromesQ95729536
Survival of Patients With Angina Pectoris Undergoing Percutaneous Coronary Intervention With Intracoronary Pressure Wire GuidanceQ96131639
P921main subjectplacebo-controlled trialQ108853737
P577publication date2020-08-28
P1433published inThe LancetQ939416
P1476titleEfficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial

Reverse relations

Q99365826Trimetazidine not beneficial after PCIcites workP2860

Search more.